DOCSLIB.ORG

Combined Index to USP 41 and NF 36, Volumes 1–5

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Combined Index to USP 41 and NF 36, Volumes 1–5 Combined Index to USP 41 and NF 36 Abaca-Acety I-1 Combined Index to USP 41 and NF 36, Volumes 1–5 Page citations refer to the pages of Volumes 1, 2, 3, 4 and 5 of USP 41±NF 36. This index is repeated in its entirety in each volume. 1–2302 Volume 1 2303–4414 Volume 2 4415–5658 Volume 3 5659–6698 Volume 4 6699–8228 Volume 5 Numbers in angle brackets such as 〈421〉 refer to chapter numbers in the General Chapters section. and (salts of) chlorpheniramine, Acetate A dextromethorphan, and methyl, 5706 pseudoephedrine, oral powder Acetate buffer, 5676 Abacavir containing at least three of the TS, 5750 oral solution, 19 following, 47 Acetazolamide, 65 sulfate, 23 and (salts of) chlorpheniramine, for injection, 66 tablets, 20 dextromethorphan, and oral suspension, 68 and lamivudine tablets, 21 pseudoephedrine, oral solution tablets, 68 Abiraterone containing at least three of the Acetic acid, 5181, 5664 acetate, 24 following, 49 ammonium acetate buffer TS, 5750 acetate tablets, 26 and (salts of) chlorpheniramine, diluted, 5181, 5664, 5690 Absolute dextromethorphan, and double-normal (2 N), 5762 alcohol, 5666 pseudoephedrine, tablets containing at glacial, 69, 5664, 5697 ether, 5664 least three of the following, 51 glacial, TS, 5750, 5754 Absorbable chlorpheniramine maleate, and and hydrocortisone otic solution, 2062 dusting powder, 1457 dextromethorphan hydrobromide irrigation, 69 gelatin film, 1929 tablets, 53 metaphosphoric, TS, 5756 gelatin sponge, 1929 and codeine phosphate capsules, 55 otic solution, 70 surgical suture, 3901 and codeine phosphate oral solution, 56 strong, TS, 5750 Absorbent and codeine phosphate oral suspension, 1 M TS, 5750 cotton, 5664 57 2 M TS, 5750 gauze, 1927 and codeine phosphate tablets, 59 Acetic acid in peptides, 6246 Acacia, 5179 dextromethorphan hydrobromide, 0.008 M Acetic acid TS, 5750 syrup, 5179 doxylamine succinate, and 0.3 N Acetic acid TS, 5750 Acarbose, 28 pseudoephedrine hydrochloride oral Acetic anhydride, 5664 Acebutolol hydrochloride, 29 solution, 60 Acetohydroxamic acid, 70 capsules, 30 and diphenhydramine citrate tablets, 61 tablets, 71 Acepromazine maleate, 32 diphenhydramine hydrochloride, and Acetone, 5182, 5664 injection, 33 pseudoephedrine hydrochloride tablets, anhydrous, 5664 tablets, 34 63 buffered, TS, 5664, 5750, 5752 Acesulfame potassium, 5180 and hydrocodone bitartrate tablets, 2053 Acetonitrile, 5664 Acetal, 5664 isometheptene mucate, and spectrophotometric, 5664 Acetaldehyde, 5664 dichloralphenazone capsules, 2251 Acetophenone, 5664 TS, 5750 and oxycodone capsules, 3107 p-Acetotoluidide, 5664 Acetaldehyde ammonia trimer trihydrate, and oxycodone tablets, 3108 Acetylacetone, 5664 5664 and pentazocine tablets, 3221 Acetyl chloride, 5664 Acetaminophen, 34 and pseudoephedrine hydrochloride Acetylcholine chloride, 72, 5665 aspirin and caffeine tablets, 42 tablets, 64 for ophthalmic solution, 73 and aspirin tablets, 41 oral solution, 37 Acetylcysteine, 74 butalbital and caffeine capsules, 596 for effervescent oral solution, 37 Acetylcysteine Index butalbital and caffeine tablets, 597 suppositories, 38 compounded solution, 75 and caffeine tablets, 44 oral suspension, 39 and isoproterenol hydrochloride inhalation capsules, 36 tablets, 39 solution, 76 and (salts of) chlorpheniramine, extended-release tablets, 40 solution, 74 dextromethorphan, and and tramadol hydrochloride oral N-Acetylglucosamine, 4417 pseudoephedrine, capsules containing at suspension, 4157 3-Acetylthio-2-methylpropanoic acid, 5665 least three of the following, 45 Acetanilide, 5664 Acetyltributyl citrate, 5183 I-2 Acety-Alumi Combined Index to USP 41 and NF 36 Acetyltriethyl citrate, 5183 Povidone±iodine topical, 3392 Alkaline N-Acetyltyrosine, 4418 Terbutaline sulfate inhalation, 3986 borate buffer, 5676 N-Acetyl-L-tyrosine ethyl ester, 5665 Thimerosal topical, 4056 cupric citrate TS, 5750 Acid Tolnaftate topical, 4135 cupric citrate TS 2, 5750 acrylic, 5665 Triamcinolone acetonide topical, 4186 cupric iodide TS, 5750 alpha lipoic, 4740 cupric tartrate TS, 5750 dehydroacetic, 5320 mercuric-potassium iodide TS, 5750 ferric chloride TS, 5750 phosphatase enzyme, 5666 ferrous sulfate TS, 5750 Agar, 5185, 5665 picrate TS, 5750 Folic, compounded oral soultion, 1866 Agarose, 5665 pyrogallol TS, 5758 iminodiacetic, 5701 Air, medical, 91 sodium hydrosulfite TS, 5751 stannous chloride TS, 5750 Air-helium certified standard, 5665 Alkyl (C12-15) benzoate, 5191 stannous chloride TS, stronger, 5750 Alanine, 92 Alkylphenoxypolyethoxyethanol, 5666 Acid-neutralizing capacity 〈301〉, 6169 L-Alanyl-L-glutamine, 4420 Allantoin, 120 Acidulated phosphate and sodium fluoride Albendazole, 93 Allopurinol, 121 topical solution, 3791 oral suspension, 93 oral suspension, 123 Acitretin, 77 tablets, 94 tablets, 123 capsules, 78 Albumen TS, 5750 Allyl isothiocyanate, 124 Statistical tools for procedure validation Albumin Almond oil, 5191 〈1210〉, 6702, 7130, 7622 bovine serum, 5665 Almotriptan Acrylic acid, 5665 human, 95 tablets, 127 Activated rAlbumin human, 5186 Almotriptan malate, 124 alumina, 5665 Albuterol, 95 Aloe, 129 charcoal, 859, 5665 sulfate, 100 Alpha magnesium silicate, 5665 tablets, 96 lipoic acid, 4740 Acyclovir, 80 extended-release tablets, 97 Alpha-chymotrypsin, 5666 capsules, 80 Alclometasone dipropionate, 100 Alpha cyclodextrin hydrate, 5666 for injection, 81 cream, 102 Alpha-(2-(methylamino)ethyl)benzyl alcohol, ointment, 82 ointment, 102 5666 oral suspension, 83 Alcohol, 103, 5665 Alphanaphthol, 5666 tablets, 84 70 percent, 80 percent, and 90 percent, Alphazurine 2G, 5745 Adamantane, 5665 5665 Alprazolam, 130 Adapalene, 85 absolute, 5666 oral suspension, 131 gel, 87 aldehyde-free, 5666 tablets, 131 Ademetionine disulfate tosylate, 4419 alpha-(2-(methylamino)ethyl)benzyl, 5666 extended-release tablets, 133 Adenine, 88 amyl, 5666 orally disintegrating tablets, 136 sulfate, 5665 tert-amyl, 5666, 5669, 5702 Alprenolol hydrochloride, 5666 Adenosine, 89 butyl, 5229 Alprostadil, 138 injection, 90 dehydrated, 105, 5666, 5686 injection, 140 Adipic acid, 5184, 5665 dehydrated isopropyl, 5666 Alteplase, 141 Admissions denaturated, 5666 for injection, 144 to NF 36, 5167 denaturated, TS, 5753 Alternative microbiological sampling methods to USP 41, xxxiii determination 〈611〉, 6358 for nonsterile inhaled and nasal products in dextrose injection, 107 〈610〉, 6356 diluted, 5188, 5666 Altretamine, 146 injection, dehydrated, 107 capsules, 147 isobutyl, 5666 Alum, 5666 Aerosol isopropyl, 5666 ammonium, 148, 5666 Bacitracin and polymyxin B sulfate topical, methyl, 5666 potassium, 148, 5719 439 neutralized, 5666, 5710 Alumina, 5666 Benzocaine, butamben, and tetracaine phenol TS, 5750 activated, 5665, 5666, 5669 hydrochloride topical, 479 n-propyl, 5666 anhydrous, 5666 Benzocaine and menthol topical, 484 rubbing, 108 aspirin, codeine phosphate, and magnesia Benzocaine topical, 470 secondary butyl, 5666 tablets, 380 Dexamethasone sodium phosphate tertiary butyl, 5666 aspirin, and magnesia tablets, 373 inhalation, 1203 Alcoholic aspirin, and magnesium oxide tablets, 375 Epinephrine bitartrate inhalation, 1533 ammonia TS, 5750 magnesia, and calcium carbonate Epinephrine inhalation, 1530 mercuric bromide TS, 5750 chewable tablets, 152 Ergotamine tartrate inhalation, 1558 potassium hydroxide TS, 5750 magnesia, calcium carbonate, and Fluticasone propionate and salmeterol potassium hydroxide TS 2, 5758 simethicone chewable tablets, 153 inhalation, 1847 TS, 5750 magnesia, and calcium carbonate oral Fluticasone propionate inhalation, 1831 Alcoholometric table, 5861 suspension, 151 Inhalation and nasal drug products: Aldehyde dehydrogenase, 5666 magnesia, and simethicone oral aerosols, sprays, and powdersÐ Alendronate sodium, 109 suspension, 155 performance quality tests 〈601〉, 6327 tablets, 110 magnesia, and simethicone chewable Isoetharine mesylate inhalation, 2245 Alfadex, 5189 tablets, 157 Isoproterenol hydrochloride inhalation, Alfentanil and magnesia oral suspension, 149 2259 hydrochloride, 112 and magnesia tablets, 150 Isoproterenol hydrochloride and injection, 113 magnesium carbonate, and magnesium phenylephrine bitartrate inhalation, 2262 Alfuzosin hydrochloride, 114 oxide tablets, 160 Index Isoproterenol sulfate inhalation, 2264 extended-release tablets, 115 and magnesium carbonate oral suspension, Lidocaine topical, 2410 Alginates assay 〈311〉, 6170 158 Metaproterenol sulfate inhalation, 2607 Alginic acid, 5190 and magnesium carbonate tablets, 159 Polymyxin B sulfate and bacitracin zinc Alizarin complexone, 5666 and magnesium trisilicate oral suspension, topical, 3350 161 Combined Index to USP 41 and NF 36 Alumi-Ammon I-3 Alumina (continued) Amiloride hydrochloride, 204 tablets, 249 and magnesium trisilicate tablets, 162 and hydrochlorothiazide tablets, 206 Amlodipine Aluminon, 5666 tablets, 205 oral suspension, 250 Aluminum, 5666 Amiloxate, 208 and benazepril hydrochloride capsules, 251 acetate topical solution, 163 Aminoacetic acid, 5667 and valsartan tablets, 253 chloride, 163 4-Aminoantipyrine, 5667 valsartan and hydrochlorothiazide tablets, chlorohydrate, 164 Aminobenzoate 257 chlorohydrate solution, 165 potassium, 209 Amlodipine besylate, 262 chlorohydrex polyethylene glycol, 166 potassium capsules, 211 tablets, 263 chlorohydrex propylene glycol, 167 potassium for oral solution, 212 Ammonia dichlorohydrate, 167 potassium tablets, 212 alcoholic TS, 5750 dichlorohydrate solution, 168 sodium, 213 detector tube, 5668 dichlorohydrex polyethylene glycol, 169 Aminobenzoic acid, 215 N 13 injection, 2955 dichlorohydrex propylene glycol, 170 gel,
Load more

Recommended publications
  • CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1
    )&f1y3X CHAPTER 29 ORGANIC CHEMICALS VI 29-1 Notes 1. Except where the context otherwise requires, the headings of this chapter apply only to: (a) Separate chemically defined organic compounds, whether or not containing impurities; (b) Mixtures of two or more isomers of the same organic compound (whether or not containing impurities), except mixtures of acyclic hydrocarbon isomers (other than stereoisomers), whether or not saturated (chapter 27); (c) The products of headings 2936 to 2939 or the sugar ethers and sugar esters, and their salts, of heading 2940, or the products of heading 2941, whether or not chemically defined; (d) Products mentioned in (a), (b) or (c) above dissolved in water; (e) Products mentioned in (a), (b) or (c) above dissolved in other solvents provided that the solution constitutes a normal and necessary method of putting up these products adopted solely for reasons of safety or for transport and that the solvent does not render the product particularly suitable for specific use rather than for general use; (f) The products mentioned in (a), (b), (c), (d) or (e) above with an added stabilizer (including an anticaking agent) necessary for their preservation or transport; (g) The products mentioned in (a), (b), (c), (d), (e) or (f) above with an added antidusting agent or a coloring or odoriferous substance added to facilitate their identification or for safety reasons, provided that the additions do not render the product particularly suitable for specific use rather than for general use; (h) The following products, diluted to standard strengths, for the production of azo dyes: diazonium salts, couplers used for these salts and diazotizable amines and their salts.
    [Show full text]
  • Clinical Study Is Nonmicronized Diosmin 600Mg As Effective As
    Hindawi International Journal of Vascular Medicine Volume 2020, Article ID 4237204, 9 pages https://doi.org/10.1155/2020/4237204 Clinical Study Is Nonmicronized Diosmin 600mg as Effective as Micronized Diosmin 900mg plus Hesperidin 100mg on Chronic Venous Disease Symptoms? Results of a Noninferiority Study Marcio Steinbruch,1 Carlos Nunes,2 Romualdo Gama,3 Renato Kaufman,4 Gustavo Gama,5 Mendel Suchmacher Neto,6 Rafael Nigri,7 Natasha Cytrynbaum,8 Lisa Brauer Oliveira,9 Isabelle Bertaina,10 François Verrière,10 and Mauro Geller 3,6,9 1Hospital Albert Einstein (São Paulo-Brasil), R. Mauricio F Klabin 357/17, Vila Mariana, SP, Brazil 04120-020 2Instituto de Pós-Graduação Médica Carlos Chagas-Fundação Educacional Serra dos Órgãos-UNIFESO (Rio de Janeiro/Teresópolis- Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 3Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Av. Alberto Torres 111, Teresópolis, RJ, Brazil 25964-004 4Faculdade de Ciências Médicas, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), Av. N. Sra. De Copacapana, 664/206, Rio de Janeiro, RJ, Brazil 22050-903 5Fundação Educacional Serra dos Órgãos-UNIFESO (Teresópolis-Brasil), Rua Prefeito Sebastião Teixeira 400/504-1, Rio de Janeiro, RJ, Brazil 25953-200 6Instituto de Pós-Graduação Médica Carlos Chagas (Rio de Janeiro-Brazil), R. General Canabarro 68/902, Rio de Janeiro, RJ, Brazil 20271-200 7Department of Medicine, Rutgers New Jersey Medical School-USA, 185 S Orange Ave., Newark, NJ 07103, USA 8Hospital Universitário Pedro Ernesto, Universidade Estadual do Rio de Janeiro (UERJ) (Rio de Janeiro-Brazil), R. Hilário de Gouveia, 87/801, Rio de Janeiro, RJ, Brazil 22040-020 9Universidade Federal do Rio de Janeiro (UFRJ) (Rio de Janeiro-Brazil), Av.
    [Show full text]
  • Download PDF About Minerals Sorted by Mineral Name
    MINERALS SORTED BY NAME Here is an alphabetical list of minerals discussed on this site. More information on and photographs of these minerals in Kentucky is available in the book “Rocks and Minerals of Kentucky” (Anderson, 1994). APATITE Crystal system: hexagonal. Fracture: conchoidal. Color: red, brown, white. Hardness: 5.0. Luster: opaque or semitransparent. Specific gravity: 3.1. Apatite, also called cellophane, occurs in peridotites in eastern and western Kentucky. A microcrystalline variety of collophane found in northern Woodford County is dark reddish brown, porous, and occurs in phosphatic beds, lenses, and nodules in the Tanglewood Member of the Lexington Limestone. Some fossils in the Tanglewood Member are coated with phosphate. Beds are generally very thin, but occasionally several feet thick. The Woodford County phosphate beds were mined during the early 1900s near Wallace, Ky. BARITE Crystal system: orthorhombic. Cleavage: often in groups of platy or tabular crystals. Color: usually white, but may be light shades of blue, brown, yellow, or red. Hardness: 3.0 to 3.5. Streak: white. Luster: vitreous to pearly. Specific gravity: 4.5. Tenacity: brittle. Uses: in heavy muds in oil-well drilling, to increase brilliance in the glass-making industry, as filler for paper, cosmetics, textiles, linoleum, rubber goods, paints. Barite generally occurs in a white massive variety (often appearing earthy when weathered), although some clear to bluish, bladed barite crystals have been observed in several vein deposits in central Kentucky, and commonly occurs as a solid solution series with celestite where barium and strontium can substitute for each other. Various nodular zones have been observed in Silurian–Devonian rocks in east-central Kentucky.
    [Show full text]
  • Compositions Comprising Drospirenone Molecularly
    (19) & (11) EP 1 748 756 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: of the grant of the patent: A61K 9/00 (2006.01) A61K 9/107 (2006.01) 29.04.2009 Bulletin 2009/18 A61K 9/48 (2006.01) A61K 9/16 (2006.01) A61K 9/20 (2006.01) A61K 9/14 (2006.01) (2006.01) (2006.01) (21) Application number: 05708751.2 A61K 9/70 A61K 31/565 (22) Date of filing: 10.03.2005 (86) International application number: PCT/IB2005/000665 (87) International publication number: WO 2005/087194 (22.09.2005 Gazette 2005/38) (54) COMPOSITIONS COMPRISING DROSPIRENONE MOLECULARLY DISPERSED ZUSAMMENSETZUNGEN AUS DROSPIRENON IN MOLEKULARER DISPERSION DES COMPOSITIONS CONTENANT DROSPIRENONE A DISPERSION MOLECULAIRE (84) Designated Contracting States: (72) Inventors: AT BE BG CH CY CZ DE DK EE ES FI FR GB GR • FUNKE, Adrian HU IE IS IT LI LT LU MC NL PL PT RO SE SI SK TR D-14055 Berlin (DE) Designated Extension States: • WAGNER, Torsten AL BA HR MK YU 13127 Berlin (DE) (30) Priority: 10.03.2004 EP 04075713 (74) Representative: Wagner, Kim 10.03.2004 US 551355 P Plougmann & Vingtoft a/s Sundkrogsgade 9 (43) Date of publication of application: P.O. Box 831 07.02.2007 Bulletin 2007/06 2100 Copenhagen Ø (DK) (60) Divisional application: (56) References cited: 08011577.7 / 1 980 242 EP-A- 1 260 225 EP-A- 1 380 301 WO-A-01/52857 WO-A-20/04022065 (73) Proprietor: Bayer Schering Pharma WO-A-20/04041289 US-A- 5 569 652 Aktiengesellschaft US-A- 5 656 622 US-A- 5 789 442 13353 Berlin (DE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and Their Generics)
    Drospirenone-Containing Birth Control Pills (Yaz, Yasmin, Ocella, Gianvi and their generics) Drospirenone is a progestin component of some birth control pills that does some blocking of testosterone (the "male hormone" that women have, too, and the hormone that can be a part of making acne worse). This is why drospirenone-containing birth control pills are especially good at helping acne (and why they can theoretically help hirsutism and female-pattern scalp hair loss as well). Drospirenone is also a mild diuretic and is why these birth control pills do not cause the water weight gain that some birth control pills can. Any birth control pill can theoretically help acne just by evening out hormonal fluctuations, but for many birth control pills, the effects on acne is very minimal. Which birth control pills are most likely to help acne? Some birth control pills are more like testosterone and some are less like testosterone. The ones that are less like testosterone can theoretically help acne more. The drospirenone-containing birth control pills go one step further by blocking testosterone, and may show the most benefit on clearing acne. Drospirenone is a progestin that is derived from 17-alpha-spironolactone and is chemically related to the diuretic spironolactone. Spironolactone is a diuretic (used for high blood pressure) that is sometimes used off-label for the treatment of acne, hirsutism or female-pattern hair loss. Often people say that a drospirenone-containing birth control pill may be equivalent to 25mg of spironolactone. Risks : Any estrogen-containing birth control pill increases the risk of a high blood pressure, stroke, or other life-threatening blood clot, and one study showed possibly a slightly higher risk with a drospirenone-containing birth control pill.
    [Show full text]
  • Betamethasone Valerate Foam: a Look at the Clinical Data
    Review: Clinical Trial Outcomes Betamethasone valerate foam: a look at the clinical data Clin. Invest. (2014) 4(3), 259–267 Topical corticosteroids and especially betamethasone valerate (BMV) have Avner Shemer1, Nicole Sakka1 & been used topically to relieve many inflammatory skin conditions such as Dov Tamarkin*2 psoriasis and atopic dermatitis. The vehicle used to deliver topical drugs 1Department of Dermatology, the Chaim Sheba Medical Center, Affiliated with the can influence the performance of these topical applications. BMV has Tel-Aviv University, Sackler School of Medicine, traditionally been available in creams, ointments, lotions and sprays. In Tel Hashomer, Israel the early 2000s, a topical hydroethanolic BMV foam became commercially 2Foamix Ltd., 2 Holzman Street, Weizmann available. Subsequently, alcohol-free emulsion- and petrolatum-based Science Park, Rehovot 76704, Israel foam formulations were also developed. This manuscript reviews the *Author for correspondence: Tel.: +972 52 457 5677 properties of BMV foams and clinical studies that have been conducted Fax: +972 8 853 1102 to assess their efficacy and safety as treatments for scalp and non-scalp [email protected] psoriasis, as well as other dermatological inflammatory conditions. Keywords: betamethasone valerate • foam • psoriasis • topical corticosteroids Topical corticosteroids have been ranked in four groups consisting of seven classes ranging from ultra-high potency preparations (class 1) to low-potency prepara- tions (class 7). Betamethasone valerate (BMV) is a mid-potency corticosteroid (class 3–5, depending on the dosage form), used topically to relieve inflammatory skin conditions. It is used as a treatment for psoriasis, atopic dermatitis and other corticosteroid-responsive dermatoses. The vehicle used to deliver topical drugs can influence the performance of these drugs.
    [Show full text]
  • Albany-Molecular-Research-Regulatory
    PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF A Abiraterone Malta • Benztropine Mesylate Cedarburg • Adenosine Rozzano - Quinto de' Stampi • • * Betaine Citrate Anhydrous Bon Encontre • Betametasone-17,21- Alcaftadine Spain Spain • • Dipropionate Sterile • Alclometasone-17, 21- Spain Betamethasone Acetate Spain Dipropionate • • Altrenogest Spain • • Betamethasone Base Spain Amphetamine Aspartate Rensselaer Betamethasone Benzoate Spain * Monohydrate Milled • Betamethasone Valerate Amphetamine Sulfate Rensselaer Spain * • Acetate Betamethasone-17,21- Argatroban Rozzano - Quinto de' Stampi Spain • • Dipropionate • • • Atenolol India • • Betamethasone-17-Valerate Spain • • Betamethasone-21- Atracurium Besylate Rozzano - Quinto de' Stampi Spain • Phosphate Disodium Salt • • Bromfenac Monosodium Atropine Sulfate Cedarburg Lodi * • Salt Sesquihydrate • • Azanidazole Lodi Bromocriptine Mesylate Rozzano - Quinto de' Stampi • • • • • Azelastine HCl Rozzano - Quinto de' Stampi • • Budesonide Spain • • Aztreonam Rozzano - Valle Ambrosia • • Budesonide Sterile Spain • • B Bamifylline HCl Bon Encontre • Butorphanol Tartrate Cedarburg • Beclomethasone-17, 21- Spain Capecitabine Lodi Dipropionate • C • 2 *Please contact our Accounts Managers in case you are interested in this API. 3 PRODUCT CATALOGUE API COMMERCIAL US EU Japan US EU Japan API Name Site CEP India API Name Site CEP India DMF DMF DMF DMF DMF DMF Dexamethasone-17,21- Carbimazole Bon Encontre Spain • Dipropionate
    [Show full text]
  • Ricini Oleum
    PHARMACOGNOSY II PHAR306 6th Semester 5th Lecture Prof. Dr. Müberra Koşar Ass. Prof. Dr. Aybike Yektaoğlu Eastern Mediterranean University Faculty of Pharmacy Department of Pharmacognosy PHARMACEUTICAL FIXED OILS AND ANIMAL FATS FIXED OILS & ANIMAL FATS Amygdalae oleum • “Almond oil” • obtained by crushing of the seeds of two varieties Prunus dulcis var. dulcis or P. dulcis var. amara (Rosaceae) in the cold • Almond oil is obtained in the Mediterranean countries (Italy, France, Spain and North Africa) where its culture is obtained • The only difference between the two varieties is the cyanogenic glycoside content of the var. amara FIXED OILS&ANIMAL FATS Amygdalae oleum • seeds carries 40-55% fixed oil • the refined oil mainly contains oleic acid (62-86%), linoleic (20- 30%), palmitic (4-9%) • Amydalae oleum raffinatum (Almond oil, refined) (Eur.Pu.) • Amydalae oleum virginale (Almond oil, virgin) (Eur.Ph.) • major used in cosmetology and dermatology • used as a carrier in oily injectable preparations FIXED OILS&ANIMAL FATS Arachidis oleum • “Arachis oil, Peanut oil” – “Peanut butter” • Arachis hypogaea (Fabaceae) • cultivated in South America, China, India, Australia, and West Africa • due to various genotypes they vary in fatty acid content • the seeds are cold-pressed • they have similar properties as olive oil • most suitable oil for added for embedding purposes into other oils (e.g. olive oil) FIXED OILS&ANIMAL FATS Arachidis oleum - content • seeds carries 40-50% fixed oil • 50-65% oleic acid • 18-30% linoleic acid • 8-10% palmitic
    [Show full text]
  • Information for the User ZYTIGA 500 Mg Film-Coated Tablets Abiraterone
    Package leaflet: Information for the user ZYTIGA 500 mg film-coated tablets abiraterone acetate Read all of this leaflet carefully before you start taking this medicine because it contains important information for you. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. What is in this leaflet: 1. What ZYTIGA is and what it is used for 2. What you need to know before you take ZYTIGA 3. How to take ZYTIGA 4. Possible side effects 5. How to store ZYTIGA 6. Contents of the pack and other information 1. What ZYTIGA is and what it is used for ZYTIGA contains a medicine called abiraterone acetate. It is used to treat prostate cancer in adult men that has spread to other parts of the body. ZYTIGA stops your body from making testosterone; this can slow the growth of prostate cancer. When ZYTIGA is prescribed for the early stage of disease where it is still responding to hormone therapy, it is used with a treatment that lowers testosterone (androgen deprivation therapy ). When you take this medicine your doctor will also prescribe another medicine called prednisone or prednisolone. This is to lower your chances of getting high blood pressure, having too much water in your body (fluid retention), or having reduced levels of a chemical known as potassium in your blood.
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • Comparative Assessment of Response to Cadmium in Heavy Metal-Tolerant Shrubs Cultured in Vitro
    Water Air Soil Pollut (2017) 228: 304 DOI 10.1007/s11270-017-3488-0 Comparative Assessment of Response to Cadmium in Heavy Metal-Tolerant Shrubs Cultured In Vitro A. Wiszniewska & E. Hanus-Fajerska & E. Muszyńska & S. Smoleń Received: 18 April 2017 /Accepted: 12 July 2017 /Published online: 26 July 2017 # The Author(s) 2017. This article is an open access publication Abstract Two species of Pb-adapted shrubs, Alyssum higher biomass accretion. Both species accumulated Cd in montanum and Daphne jasminea, were evaluated developed organs, and its content increased with increas- in vitro for their tolerance to elevated concentrations of ing CdCl2 dose. Interestingly, D. jasminea accumulated cadmium. Shoot cultures were treated with 0.5, 2.5, and higher amounts of Cd in the roots than A. montanum and 5.0 μM CdCl2 for 16 weeks and analyzed for their immobilized this metal in the root system. On the contrary, organogenic response, biomass accretion, pigment con- A. montanum translocated some part of accumulated Cd tent, and macronutrient status. Cadmium accumulation to the shoots, but with low efficiency. In the presence of and its root-to-shoot translocation were also determined. Cd, A. montanum maintained macronutrient homeostasis In both species, rooted microplantlets, suitable for accli- and synthesized higher amounts of phytosynthetic pig- matization, were obtained in the presence of Cd applied as ments in the shoots. D. jasminea accumulated root bio- selection agent. In A. montanum, low and moderate dose mass, immobilized Cd, and restricted its translocation at of Cd stimulated multiplication, rooting, and biomass the expense of nutrient balance. Considering remediation production.
    [Show full text]
  • Abiraterone Acetate for Chemotherapy-Naive
    Fan et al. BMC Urology (2018) 18:110 https://doi.org/10.1186/s12894-018-0416-6 RESEARCHARTICLE Open Access Abiraterone acetate for chemotherapy- naive metastatic castration-resistant prostate cancer: a single-centre prospective study of efficacy, safety, and prognostic factors Liancheng Fan†, Baijun Dong†, Chenfei Chi†, Yanqing Wang†, Yiming Gong†, Jianjun Sha, Jiahua Pan, Xun Shangguan, Yiran Huang, Lixin Zhou* and Wei Xue* Abstract Background: To evaluate the efficacy and safety of abiraterone acetate (AA) plus prednisone compared with prednisone alone in Asian patients with chemotherapy-naive metastatic castration-resistant prostate cancer (mCRPC), and to identify predictive factors. Methods: We reviewed the medical records of 60 patients with chemotherapy-naive mCRPC at Renji Hospital who were treated with AA plus prednisone (n = 43) or prednisone alone (n = 17). All patients were assessed for prostate- specific antigen (PSA) response, PSA progression-free survival (PSA PFS), radiographic progression-free survival (rPFS), and overall survival (OS). The ability of several parameters to predict PSA PFS, rPFS, and OS was studied. Results: The median follow-up time was 14.0 months (range 7.0–18.5 months), at which time 19 death events had been reported: 11 in the AA + prednisone group and 8 in the prednisone group. The AA + prednisone group had significantly longer median PSA PFS (10.3 vs 3.0 months, P < 0.001), rPFS (13.9 vs 3.9 months, P < 0.001), and OS (23. 3 vs 17.5 months, P = 0.016) than the prednisone-alone group. The most frequently reported grade 3 or 4 adverse event in both the AA + prednisone and prednisone-alone groups was elevated alanine aminotransferase level in 5 of 43 patients (11.6%) and 2 of 17 patients (11.8%), respectively.
    [Show full text]